≡ Kosan’s Motilin Receptor Agonist, Licensed To Pfizer, Enters Phase 1 Clinical Trial In Gastroesophageal Reflux Disease Part 2
About Rigel Rigel is a clinical-stage drug commencement general public that discover and develop advanced, small-molecule drugs in structure of the nurture of inflammatory bug, cancer and viral diseases. Our aim is to profile one unknown investigational new drug (IND) standing surrounded by a evocative implication all year. We have achieve this goal […]
